AMAM

Ambrx Biopharma (AMAM)

Ambrx Biopharma Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:AMAM

1 2 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/03/19	03:45	Edgar (US Regulatory)	Form 15-12G - Securities registration termination [Section 12(g)]	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/13	05:55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/11	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/09	03:39	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/09	03:34	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/09	03:29	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/09	03:24	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/09	03:20	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/08	03:23	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/07	22:49	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/07	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/02/24	04:09	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/02/22	22:31	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/02/22	22:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/02/13	03:43	PR Newswire (US)	Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/01/11	05:07	PR Newswire (US)	Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law Firm	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/01/09	04:54	Dow Jones News	Trending: Johnson & Johnson and Merck & Co. Announce Acquisitions	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/01/09	00:04	Dow Jones News	Ambrx Biopharma Shares Double on $2 Billion Acquisition by Johnson & Johnson	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/01/08	22:12	Dow Jones News	Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 Billion	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/10/24	06:19	Edgar (US Regulatory)	Form 15-12G - Securities registration termination [Section 12(g)]	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/09/16	05:27	Edgar (US Regulatory)	Form DEFM14A - Definitive proxy statement relating to merger or acquisition	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/09/16	05:24	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/09/07	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/08/26	06:23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/07/19	22:49	Dow Jones News	Ambrx Biopharma Gets Fast Track Designation for ARX517 Cancer Treatment	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/06/29	05:46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/06/29	05:45	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/06/29	05:07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/06/29	05:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/06/10	05:12	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:AMAM	Ambrx Biopharma Inc